Pharma Services
Understanding the Future of Medicine and What it Means for Your Company
Crosstree’s advisors have end-to-end experience in the pharma services, research, and development space, and has worked with companies positioned from discovery and preclinical, to clinical development and lab services, to supply and commercialization.
As pharmaceutical companies shift toward combination product development programs and more complex test-and-treat therapies, patient-centricity has become a focal point. Crosstree understands how each company supports the patient’s journey — either directly or secondarily by facilitating better research and development — and can identify the most viable buyers based on current and emerging needs.
Crosstree has provided buy- and sell-side financial guidance through the rise of targeted medicine. Today, Crosstree is spearheading transactions for innovative growth companies and established market leaders shifting toward precision and specialty medicine strategies.

Pharma Services
Drug
Development
.png?width=100&name=Untitled%20design%20(75).png)
Pharma Supply
Chain
Pharma
Commerce
Pharma
Technology
DRUG DEVELOPMENT
- Clinical Services
- eClinical
- Lab Services
PHARMA SUPPLY CHAIN
- CDMO
- Drug Supply Chain Regulatory Audit
- Pharma Supply Chain Technology
- Pharmaceutical Logistics
- Pharmacy
PHARMA COMMERCE
- Pharma Commerce Technology
- Pharma Market Access
- Regulatory and Medical Affairs
PHARMA TECHNOLOGY
- e-Clinical
- Pharma Commerce Technology
- Pharma Supply Chain Technology
Bluebooks
Explore our industry-specific Bluebooks for comprehensive monthly coverage of M&A, recapitalization, and growth financing transactions, along with year-on-year comparisons. Subscribe to your relevant BlueBook for valuable insights today.

Latest Pharma Services Transactions
.png)
Deep 6 AI Acquired by Tempus

Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities

Pinnacle Clinical Research Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network

Pinnacle Clinical Research Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network

Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
.V3-1.png)
Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally

Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities

Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities

VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities

Grant Avenue Capital Recapitalizes CREO

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform

SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU

Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings

Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
